Immupharma plots patient recruitment for Lupzor trials

Drug discovery and development outfit Immupharma has progressed its managed access programme on Lupzor as planned, with patient recruitment in France and the UK expected to follow the firm's analysis of regulatory processes across the EU.

FTSE AIM All-Share

738.76

15:15 01/11/24

n/a

Immupharma

1.59p

15:04 01/11/24

0.31%

0.01p

Pharmaceuticals & Biotechnology

21,053.75

15:14 01/11/24

0.57%

118.90

Immupharma told investors on Friday that it was "delighted" to be progressing with necessary activities on its late-stage treatment for auto-immune disease Lupus and that it "remained focused" on achieving full regulatory approval for the drug.

Elsewhere, Immupharma noted that an agreement regarding a clinical development collaboration of its Nucant cancer programme with Incanthera had progressed and that the pair was in the process of finalising a definitive licence agreement.

Lastly, the AIM-listed group said active discussions regarding the appointment of a new NOMAD were still ongoing and added it would update shareholders on its progress "in the near future."

As of 1025 GMT, Immupharma shares had ticked up 0.13% to 12.27p.